US 12,448,449 B2
Immune targeting molecules and uses thereof
Iqbal S. Grewal, Newtown, PA (US); Michael Riis Hansen, Broomall, PA (US); Rajkumar Ganesan, Blue Bell, PA (US); and Sanjaya Singh, Blue Bell, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed on Sep. 10, 2021, as Appl. No. 17/472,186.
Claims priority of provisional application 63/237,974, filed on Aug. 27, 2021.
Claims priority of provisional application 63/165,050, filed on Mar. 23, 2021.
Claims priority of provisional application 63/077,458, filed on Sep. 11, 2020.
Prior Publication US 2022/0089736 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2818 (2013.01) [C07K 16/2809 (2013.01); C07K 16/2878 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/92 (2013.01)] 5 Claims
OG exemplary drawing
 
1. An antibody that binds to CD28 comprising:
(1) (i) a VH comprising the amino acid sequence of SEQ ID NO:31; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:32;
(2) (i) a VH comprising the amino acid sequence of SEQ ID NO:65; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:66;
(3) (i) a VH comprising the amino acid sequence of SEQ ID NO:99; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:100;
(4) (i) a VH comprising the amino acid sequence of SEQ ID NO:133; and (ii) a VL comprising the amino acid sequence of SEQ ID NO: 134.